Skip to main content
SpringerLink
Log in

Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma

  • Review
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Positron emission tomography/computed tomography (PET/CT) has dramatically altered the landscape of noninvasive glioma evaluation, offering complementary insights to those gained through magnetic resonance imaging (MRI). PET/CT scans enable a multifaceted analysis of glioma biology, supporting clinical applications from grading and differential diagnosis to mapping the full extent of tumors and planning subsequent treatments and evaluations. With a broad array of specialized radiotracers, researchers and clinicians can now probe various biological characteristics of gliomas, such as glucose utilization, cellular proliferation, oxygen deficiency, amino acid trafficking, and reactive astrogliosis. This review aims to provide a recent update on the application of versatile PET/CT radiotracers in glioma research and clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.

References

  1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17 Suppl 4:iv1-iv62.

  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

    Article  PubMed  Google Scholar 

  3. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-Methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53:1709–15.

    Article  PubMed  Google Scholar 

  5. Heiss WD. PET in gliomas. Overview of current studies. Nuklearmedizin. 2014;53:163–71; quiz N32.

  6. Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer. 2014;33:16–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190:W365–9.

    Article  PubMed  Google Scholar 

  8. Kim D, Kim S, Kim SH, Chang JH, Yun M. Prediction of overall survival based on isocitrate dehydrogenase 1 mutation and 18F-FDG uptake on PET/CT in patients with cerebral gliomas. Clin Nucl Med. 2018;43:311–6.

    Article  PubMed  Google Scholar 

  9. Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic accuracy of PET for differentiating true glioma progression from post treatment-related changes: a systematic review and meta-analysis. Front Neurol. 2021;12: 671867.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Treglia G, Muoio B, Trevisi G, Mattoli MV, Albano D, Bertagna F, et al. Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. Int J Mol Sci. 2019;20:4669.

  11. Ouyang ZQ, Zheng GR, Duan XR, Zhang XR, Ke TF, Bao SS, et al. Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis. Quant Imaging Med Surg. 2023;13:4943–59.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57.

    Article  CAS  PubMed  Google Scholar 

  13. Piccardo A, Albert NL, Borgwardt L, Fahey FH, Hargrave D, Galldiks N, et al. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2022;49:3852–69.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632–51.

    Article  PubMed  Google Scholar 

  15. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323–9.

    Article  PubMed  Google Scholar 

  16. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1–4.

    Article  ADS  CAS  PubMed  Google Scholar 

  17. Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006;5:937–48.

    Article  PubMed  Google Scholar 

  18. Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12:148–57.

    Article  PubMed  Google Scholar 

  19. Kim D, Ko HY, Lee S, Lee YH, Ryu S, Kim SY, et al. Glucose loading enhances the value of (18)F-FDG PET/CT for the characterization and delineation of cerebral gliomas. Cancers (Basel). 2020;12:1977.

  20. Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen B, Mawlawi O, et al. Delayed FDG PET provides superior glioblastoma conspicuity compared to conventional image timing. Front Neurol. 2021;12: 740280.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32:1185–96.

    Article  CAS  PubMed  Google Scholar 

  22. Pollard PJ, Ratcliffe PJ. Cancer. Puzzling patterns of predisposition. Science. 2009;324:192–4.

    Article  ADS  CAS  PubMed  Google Scholar 

  23. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.

    Article  CAS  PubMed  Google Scholar 

  24. Chen JR, Yao Y, Xu HZ, Qin ZY. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore). 2016;95: e2583.

    Article  CAS  PubMed  Google Scholar 

  25. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–45.

    CAS  PubMed  Google Scholar 

  26. Isselbacher KJ. Sugar and amino acid transport by cells in culture–differences between normal and malignant cells. N Engl J Med. 1972;286:929–33.

    Article  CAS  PubMed  Google Scholar 

  27. Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959;19:1030–9.

    CAS  PubMed  Google Scholar 

  28. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18:500–9.

    Article  CAS  PubMed  Google Scholar 

  29. Kinoshita M, Arita H, Goto T, Okita Y, Isohashi K, Watabe T, et al. A novel PET index, 18F-FDG-11C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med. 2012;53:1701–8.

    Article  PubMed  Google Scholar 

  30. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–11.

    CAS  PubMed  Google Scholar 

  31. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci. 2010;17:43–9.

    Article  PubMed  Google Scholar 

  32. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.

    Article  CAS  PubMed  Google Scholar 

  33. Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35.

    Article  CAS  PubMed  Google Scholar 

  34. Galldiks N, Kracht LW, Dunkl V, Ullrich RT, Vollmar S, Jacobs AH, et al. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [(1)(1)C]-methionine positron emission tomography. Mol Imaging. 2011;10:453–9.

    Article  CAS  PubMed  Google Scholar 

  35. Falk Delgado A, Falk DA. Discrimination between primary low-grade and high-grade glioma with (11)C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. Br J Radiol. 2018;91:20170426.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mattoli MV, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I, et al. Dynamic (11)C-methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence. Cancers (Basel). 2021;13:4777.

  37. Bag AK, Wing MN, Sabin ND, Hwang SN, Armstrong GT, Han Y, et al. (11)C-Methionine PET for identification of pediatric high-grade glioma recurrence. J Nucl Med. 2022;63:664–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L, et al. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. Neuro Oncol. 2022;24:1546–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367–73.

    CAS  PubMed  Google Scholar 

  40. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–12.

    CAS  PubMed  Google Scholar 

  41. Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P, et al. Differential uptake of O-(2–18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007;48:2056–62.

    Article  CAS  PubMed  Google Scholar 

  42. Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006;33:932–9.

    Article  PubMed  Google Scholar 

  43. Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18:426–34.

    Article  CAS  PubMed  Google Scholar 

  44. Skoblar Vidmar M, Doma A, Smrdel U, Zevnik K, Studen A. The value of FET PET/CT in recurrent glioma with a different IDH mutation status: the relationship between imaging and molecular biomarkers. Int J Mol Sci. 2022;23:6787.

  45. Matsubara K, Watabe H, Kumakura Y, Hayashi T, Endres CJ, Minato K, et al. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for [(1)(8)F]FDOPA PET by a model with detailed dopamine pathway. Synapse. 2011;65:751–62.

    Article  CAS  PubMed  Google Scholar 

  46. Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993;13:881–8.

    Article  CAS  PubMed  Google Scholar 

  47. Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2013;111:11–8.

    Article  CAS  PubMed  Google Scholar 

  48. Zaragori T, Ginet M, Marie PY, Roch V, Grignon R, Gauchotte G, et al. Use of static and dynamic [(18)F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression. EJNMMI Res. 2020;10:56.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kim D, Chun JH, Kim SH, Moon JH, Kang SG, Chang JH, et al. Re-evaluation of the diagnostic performance of (11)C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur J Nucl Med Mol Imaging. 2019;46:1678–84.

    Article  CAS  PubMed  Google Scholar 

  51. Ponisio MR, McConathy JE, Dahiya SM, Miller-Thomas MM, Rich KM, Salter A, et al. Dynamic (18)F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neurooncol Pract. 2020;7:656–67.

    PubMed  PubMed Central  Google Scholar 

  52. Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1-11C]acetate–an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot. 1982;33:505–12.

    Article  CAS  PubMed  Google Scholar 

  53. Nicklas WJ, Clarke DD. Decarboxylation studies of glutamate, glutamine, and aspartate from brain labelled with [1-14C]acetate, L-[U-14C]-aspartate, and L-[U-14C]glutamate. J Neurochem. 1969;16:549–58.

    Article  CAS  PubMed  Google Scholar 

  54. Waniewski RA, Martin DL. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci. 1998;18:5225–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cruz NF, Lasater A, Zielke HR, Dienel GA. Activation of astrocytes in brain of conscious rats during acoustic stimulation: acetate utilization in working brain. J Neurochem. 2005;92:934–47.

    Article  CAS  PubMed  Google Scholar 

  56. Wyss MT, Magistretti PJ, Buck A, Weber B. Labeled acetate as a marker of astrocytic metabolism. J Cereb Blood Flow Metab. 2011;31:1668–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cerdan S, Kunnecke B, Seelig J. Cerebral metabolism of [1,2–13C2]acetate as detected by in vivo and in vitro 13C NMR. J Biol Chem. 1990;265:12916–26.

    Article  CAS  PubMed  Google Scholar 

  58. Hassel B, Sonnewald U, Fonnum F. Glial-neuronal interactions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C NMR spectroscopic study. J Neurochem. 1995;64:2773–82.

    Article  CAS  PubMed  Google Scholar 

  59. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med. 2014;20:886–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H(2)O(2)(-) production. Nat Neurosci. 2020;23:1555–66.

    Article  CAS  PubMed  Google Scholar 

  61. Heo JY, Nam MH, Yoon HH, Kim J, Hwang YJ, Won W, et al. Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson’s disease. Curr Biol. 2020;30(276–91): e9.

    Google Scholar 

  62. Nam MH, Cho J, Kwon DH, Park JY, Woo J, Lee JM, et al. Excessive astrocytic GABA causes cortical hypometabolism and impedes functional recovery after subcortical stroke. Cell Rep. 2020;32: 107975.

    Article  CAS  PubMed  Google Scholar 

  63. Nagashima G, Suzuki R, Asai J, Fujimoto T. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002;104:125–31.

    Article  PubMed  Google Scholar 

  64. Nam MH, Ko HY, Kim D, Lee S, Park YM, Hyeon SJ, et al. Visualizing reactive astrocyte-neuron interaction in Alzheimer’s disease using 11C-acetate and 18F-FDG. Brain. 2023;146:2957–74.

    Article  PubMed  Google Scholar 

  65. Takata K, Kato H, Shimosegawa E, Okuno T, Koda T, Sugimoto T, et al. 11C-Acetate PET imaging in patients with multiple sclerosis. PLoS ONE. 2014;9: e111598.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  66. Kato H, Okuno T, Isohashi K, Koda T, Shimizu M, Mochizuki H, et al. Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET. J Cereb Blood Flow Metab. 2021;41:369–79.

    Article  CAS  PubMed  Google Scholar 

  67. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-Acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–6.

    CAS  PubMed  Google Scholar 

  68. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.

    Article  PubMed  Google Scholar 

  69. Ho CL, Yu SC, Yeung DW. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213–21.

    PubMed  Google Scholar 

  70. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159:1603–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Masui K, Cavenee WK, Mischel PS. mTORC2 and metabolic reprogramming in GBM: at the interface of genetics and environment. Brain Pathol. 2015;25:755–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, et al. PET imaging of brain astrocytoma with 1–11C-acetate. Eur J Nucl Med Mol Imaging. 2006;33:420–7.

    Article  PubMed  Google Scholar 

  73. Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-Acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10:281–7.

    Article  CAS  PubMed  Google Scholar 

  74. Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y. Grading of brain glioma with 1–11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol. 2008;35:171–6.

    Article  CAS  PubMed  Google Scholar 

  75. Kim S, Kim D, Kim SH, Park MA, Chang JH, Yun M. The roles of (11)C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. Eur J Nucl Med Mol Imaging. 2018;45:1012–20.

    Article  PubMed  Google Scholar 

  76. Kim D, Cho A, Hwang SH, Jo K, Chang JH, Yun M. Choroid plexus as the best reference region for standardized uptake value analysis on C11-acetate PET/CT for grading and predicting prognosis in patients with cerebral gliomas. Nucl Med Mol Imaging. 2020;54:274–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Kim D, Ko HY, Chung JI, Park YM, Lee S, Kim SY, et al. Visualizing cancer-originating acetate uptake through MCT1 in reactive astrocytes in the glioblastoma tumor microenvironment. Neuro Oncol. 2023. https://doi.org/10.1093/neuonc/noad243.

  78. Kim D, Chun JH, Yi JH, Ko HY, Chung JI, Lee M, et al. 11 C-Acetate PET/CT detects reactive astrogliosis helping glioma classification. Clin Nucl Med. 2022;47:863–8.

    Article  PubMed  Google Scholar 

  79. Diep YN, Park HJ, Kwon JH, Tran M, Ko HY, Jo H, et al. Astrocytic scar restricting glioblastoma via glutamate-MAO-B activity in glioblastoma-microglia assembloid. Biomater Res. 2023;27:71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–8.

    CAS  PubMed  Google Scholar 

  81. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med. 2007;37:429–39.

    Article  PubMed  Google Scholar 

  82. Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, et al. 3′-Deoxy-3′-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012;53:1904–10.

    Article  CAS  PubMed  Google Scholar 

  83. Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54:903–12.

    Article  CAS  PubMed  Google Scholar 

  84. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315–23.

    CAS  PubMed  Google Scholar 

  85. Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878–83.

    Article  PubMed  Google Scholar 

  86. Shinomiya A, Kawai N, Okada M, Miyake K, Nakamura T, Kushida Y, et al. Evaluation of 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging. 2013;40:175–85.

    Article  CAS  PubMed  Google Scholar 

  87. Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. 2014;9: e95830.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  88. Ferdova E, Ferda J, Baxa J, Tupy R, Mracek J, Topolcan O, et al. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT. Anticancer Res. 2015;35:955–9.

    CAS  PubMed  Google Scholar 

  89. Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:319–26.

    Article  CAS  PubMed  Google Scholar 

  91. Hirata K, Yamaguchi S, Shiga T, Kuge Y, Tamaki N. The roles of hypoxia imaging using (18)F-fluoromisonidazole positron emission tomography in glioma treatment. J Clin Med. 2019;8:1088.

  92. Hammond EM, Asselin MC, Forster D, O’Connor JP, Senra JM, Williams KJ. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol (R Coll Radiol). 2014;26:277–88.

    Article  CAS  PubMed  Google Scholar 

  93. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981;43:546–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum A. 1986;37:599–605.

    Article  CAS  PubMed  Google Scholar 

  95. Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513–20.

    Article  PubMed  Google Scholar 

  96. Collet S, Guillamo JS, Berro DH, Chakhoyan A, Constans JM, Lechapt-Zalcman E, et al. Simultaneous mapping of vasculature, hypoxia, and proliferation using dynamic susceptibility contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma. J Nucl Med. 2021;62:1349–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Reuss AM, Groos D, Buchfelder M, Savaskan N. The acidic brain-glycolytic switch in the microenvironment of malignant glioma. Int J Mol Sci. 2021;22:5518.

  98. Barajas RF Jr, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, et al. Assessing biological response to bevacizumab using 18F-fluoromisonidazole PET/MR imaging in a patient with recurrent anaplastic astrocytoma. Case Rep Radiol. 2015;2015: 731361.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by NRF-2018M3C7A1056898, NRF-2020R1A2B5B01098109, and RS-2022-00144475 from the National Research Foundation (NRF) of Korea to M.Y.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea

    Dongwoo Kim & Mijin Yun

  2. Department of Radiology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, 07441, Republic of Korea

    Suk-Hyun Lee

  3. Department of Nuclear Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, 14068, Republic of Korea

    Hee Sung Hwang

  4. Department of Nuclear Medicine, National Health Insurance Service Ilsan Hospital, Goyang, 10444, Republic of Korea

    Sun Jung Kim

Authors
  1. Dongwoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suk-Hyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hee Sung Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mijin Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dongwoo Kim and Mijin Yun were responsible for the study design and writing the manuscript. The first draft of the manuscript was written by Dongwoo Kim and Mijin Yun, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mijin Yun.

Ethics declarations

Conflict of Interest

Dongwoo Kim, Suk-Hyun Lee, Hee Sung Hwang, Sun Jung Kim, and Mijin Yun declare no competing interests..

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D., Lee, SH., Hwang, H.S. et al. Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma. Nucl Med Mol Imaging (2024). https://doi.org/10.1007/s13139-024-00847-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13139-024-00847-4

Keywords

Search

Navigation